In head-to-head trials like SURMOUNT-5, tirzepatide has demonstrated greater weight loss compared to single GLP-1 receptor agonists like semaglutide
Because retatrutide targets all three receptors GLP-1, GIP, and GCG it is called a "triple G" or GGG tri-agonist
Pharmacodynamics: BPC-157 is a cytoprotective peptide derived from body protection compounds that promotes angiogenesis, stabilizes endothelial function, and accelerates tissue repair by modulating growth factors and inflammatory mediators
WahlstromKLHuffMLEmmonsEBFreemanJHNarayananNSMcIntyreCKet al
GIP enhances insulin sensitivity, improves nutrient utilization, and may have direct effects on fat tissue metabolism
The participants of the STEP 4 study who stopped taking semaglutide regained 6.9% of their body weight over 48 weeks